Brian Corrigan, Ph.D.

Principal Consultant, Strategic Advisory Solutions

Dr. Brian Corrigan brings nearly 30 years of expertise in clinical pharmacology, quantitative modeling, and global drug development to Metrum Research Group. As former Senior Vice President of Translational Clinical Sciences at Pfizer, he led initiatives in precision medicine, business development, and innovative regulatory strategies. A champion for inclusivity, he founded Pfizer’s Men as Allies initiative and served as President of the International Society of Pharmacometrics. At MetrumRG, Dr. Corrigan provides strategic guidance to biopharma leaders, empowering data-driven decisions that maximize pipeline value.

Recent publications by this scientist

Shortening the Regulatory Submission Critical Path via MIDD Acceleration: A Multi-Trial Phase 3 Case Study

October 9, 2026

Regulatory submissions for new drugs (NDAs/BLAs) increasingly rely on MIDD (model-informed drug development) analyses to support dosing, labeling, and design of post-approval trial commitments. Frequently, MIDD related activities (data cleaning/prep, analysis, summary document preparation) are on the filing critical path (CP) following completion of the final registration studies, with delays directly impacting time to file. These delays impact overall medicine value and access for patients.

Download PDF

Expanding Quantitative Medicines’ Reach: Systems and Methods to Enhance R&D Productivity and Decision-Making in the Agentic Era

October 6, 2026

Brian W. Corrigan, Eric Anderson, Andrew Tredennick, Luis Martinez Lomeli, Megan Cala Pane, Tyler Dunlap, Brian Davis, James Rogers, Marc R. Gastonguay
First published 05 September 2026 in Clinical and Translational Science, Volume 19, Issue 9

Despite integration of artificial intelligence (AI) into drug discovery and an expanding global medicines pipeline, new drug approvals have declined, highlighting a paradox in biopharma: More drugs discovered, but less approvals, higher costs, and longer timelines. Reasons for the decreased research and development (R&D) efficiency are multifactorial, in part driven by the complexity of new modalities, difficult targets and indications, and persistence of cognitive biases in clinical decision-making. One proposed solution to address R&D productivity challenges includes the adoption of organization-wide quantitative decision frameworks (QDFs). QDFs have the potential to increase R&D productivity by integrating quantitative assessments of program risk and value, clinical development costs, time, and probability of success into product valuations.

Read Article

ACCELERATION OF CRITICAL PATH MODEL INFORMED DRUG DEVELOPMENT (MIDD) SUBMISSION ACTIVITIES VIA DATA AND TOOL STANDARDIZATION

March 18, 2026


ACCELERATION OF CRITICAL PATH MODEL INFORMED DRUG DEVELOPMENT (MIDD) SUBMISSION ACTIVITIES VIA DATA AND TOOL STANDARDIZATION Brian W. Corrigan¹, Matthew Riggs¹, Mike Ferguson¹, Joydeep Bhattacharya¹, Marc R. Gastonguay¹ 1 Metrum Research Group, Boston, MA, USA

Regulatory submissions for new drugs (NDAs/BLAs) increasingly rely on
pharmacometric (PK/PD) analyses to support dosing, labeling, and design of
post-approval trial commitments.
More frequently, MIDD related activities (data cleaning/prep, analysis,
summary document preparation) are on the filing critical path (CP) following
completion of the final registration studies, with delays directly impacting
time to file. These delays impact overall medicine value.
Accelerating MIDD related CP activities via methods standardization,
process automation, and proactive planning offers a potential mechanism for
increasing speed without compromising quality

Download PDF